AI has discovered new biomarkers for high-risk heart disease patients

Hypertrophic cardiomyopathy (HCM) is a condition in which muscle tissue in the heart becomes thicker, with no obvious cause. This makes the heart less able to pump blood effectively. People with HCM have a range of symptoms and it can cause death. Unfortunately, early-stage HCM can be a challenge to identify - which makes studying early-stage HCM difficult.

Owkin has created the largest global registry of over 1,000 pre-symptomatic HCM patients. We have then used AI to identify biomarkers that could indicate higher progression risk in certain patients. These findings are particularly valuable as they focus on early-stage patients, traditionally underrepresented in medical registries that typically concentrate on late-stage, symptomatic cases. These biomarkers enable more proactive monitoring and highlight the need to update treatment strategies for early-stage disease management.